Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA)
CUSIP: G9TY5A101
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Class A Ordinary Shares, par value $0.0001 per share
- Shares outstanding
- 108,236,654
- Total 13F shares
- 42,890,401
- Share change
- +906,765
- Total reported value
- $107,244,382
- Put/Call ratio
- 55%
- Price per share
- $2.50
- Number of holders
- 87
- Value change
- -$472,426
- Number of buys
- 50
- Number of sells
- 24
Quarterly Holders Quick Answers
What is CUSIP G9TY5A101?
CUSIP G9TY5A101 identifies ZURA - Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP G9TY5A101:
Top shareholders of ZURA - Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BARCLAYS PLC |
3/4/5
13F
|
10%+ Owner · Company |
0.06%
from 13F
|
2,340,240
|
$24,349,729 | — | 09 Jan 2023 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
4.5%
|
4,860,939
|
$19,735,412 | — | 30 Sep 2024 | |
| ADAR1 Capital Management, LLC |
13F
13D/G
|
Company |
3.2%
from 13D/G
|
3,770,649
|
$15,308,835 | — | 30 Sep 2024 | |
| Deep Track Capital, LP |
13F
|
Company |
3%
|
3,283,783
|
$13,332,159 | — | 30 Sep 2024 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
3%
|
3,263,672
|
$13,250,508 | — | 30 Sep 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
|
Company |
4.9%
from 13D/G
|
3,217,503
|
$13,063,062 | — | 30 Sep 2024 | |
| BRAIDWELL LP |
13F
|
Company |
2.3%
|
2,472,806
|
$10,039,592 | — | 30 Sep 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.2%
|
2,413,127
|
$9,797,296 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
2.2%
|
2,371,970
|
$9,630,199 | — | 30 Sep 2024 | |
| VR Adviser, LLC |
13F
|
Company |
1.9%
|
2,023,166
|
$8,214,054 | — | 30 Sep 2024 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.4%
|
1,500,000
|
$6,090,000 | — | 30 Sep 2024 | |
| PFIZER INC |
13D/G
3/4/5
|
Pfizer Inc. 13-5315170 · 10%+ Owner |
4.6%
|
2,970,022
|
$4,276,832 | $0 | 31 Dec 2024 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.96%
|
1,044,168
|
$4,239,322 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.84%
|
912,625
|
$3,705,638 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.75%
|
813,443
|
$3,302,578 | — | 30 Sep 2024 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.68%
|
738,718
|
$2,999,195 | — | 30 Sep 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.48%
|
518,656
|
$2,105,743 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.36%
|
395,059
|
$1,603,940 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.32%
|
344,411
|
$1,398,310 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.31%
|
336,828
|
$1,367,522 | — | 30 Sep 2024 | |
| Boxer Capital, LLC |
13F
|
Company |
0.28%
|
300,000
|
$1,218,000 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.27%
|
291,807
|
$1,184,736 | — | 30 Sep 2024 | |
| Michael Howell |
3/4/5
|
Chief Scientific Officer and Head of Translational Science |
—
mixed-class rows
|
529,904
mixed-class rows
|
$1,063,813 | — | 18 Jun 2024 | |
| Polar Asset Management Partners Inc. |
13F
|
Company |
0.24%
|
259,241
|
$1,052,518 | — | 30 Sep 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.21%
|
223,335
|
$906,740 | — | 30 Sep 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.16%
|
176,973
|
$718,510 | — | 30 Sep 2024 | |
| RAYMOND JAMES & ASSOCIATES |
13F
|
Company |
0.16%
|
171,708
|
$697,134 | — | 30 Sep 2024 | |
| Christopher Cabell |
3/4/5
|
CMO & Head of R&D |
—
class O/S missing
|
162,060
|
$648,240 | — | 18 May 2023 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.14%
|
156,626
|
$635,902 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.12%
|
130,950
|
$531,657 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.09%
|
97,374
|
$395,338 | — | 30 Sep 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.08%
|
85,872
|
$348,640 | — | 30 Sep 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.07%
|
80,912
|
$328,503 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.06%
|
63,900
|
$259,434 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.05%
|
58,961
|
$239,382 | — | 30 Sep 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.05%
|
57,858
|
$234,903 | — | 30 Sep 2024 | |
| Caption Management, LLC |
13F
|
Company |
0.05%
|
56,866
|
$230,876 | — | 30 Sep 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.04%
|
45,455
|
$184,547 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.04%
|
43,858
|
$178,063 | — | 30 Sep 2024 | |
| Palumbo Wealth Management LLC |
13F
|
Company |
0.04%
|
38,335
|
$155,641 | — | 30 Sep 2024 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.04%
|
38,999
|
$147,120 | — | 30 Sep 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.03%
|
32,098
|
$130,318 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
31,256
|
$126,900 | — | 30 Sep 2024 | |
| Forefront Analytics, LLC |
13F
|
Company |
0.03%
|
30,810
|
$125,087 | — | 30 Sep 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.03%
|
28,840
|
$117,090 | — | 30 Sep 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.03%
|
27,426
|
$111,343 | — | 30 Sep 2024 | |
| MetLife Investment Management, LLC |
13F
|
Company |
0.03%
|
27,260
|
$110,676 | — | 30 Sep 2024 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.02%
|
24,300
|
$98,658 | — | 30 Sep 2024 | |
| Corebridge Financial, Inc. |
13F
|
Company |
0.02%
|
23,738
|
$96,376 | — | 30 Sep 2024 | |
| ANGELO GORDON & CO., L.P. |
13F
|
Company |
0.02%
|
22,500
|
$91,350 | — | 30 Sep 2024 |
Institutional Holders of Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA) as of Q4 2024
As of 31 Dec 2024,
Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA) was held by
87 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
42,890,401 shares.
The largest 10 holders included
SUVRETTA CAPITAL MANAGEMENT, LLC, Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., GREAT POINT PARTNERS LLC, Pfizer Inc, BlackRock, Inc., JPMORGAN CHASE & CO, BRAIDWELL LP, Point72 Asset Management, L.P., and ADAR1 Capital Management, LLC.
This page lists
87
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
77
Q4 2024 holders
87
Holder diff
10
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.